Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in type 2 diabetic patients

Miwa, Shinnya; Inouye, Masayuki; Ohmura, Chie; Mitsuhashi, Naoki; Onuma, Tomio; Kawamori, Ryuzo

doi:10.1016/s0168-8227(03)00108-6

Cited by 21 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDA-LDL was measured by an enzyme-linked immunosorbent assay (ELISA) method based on the principle previously reported by Kotani et al [14]. To estimate the extent of cholesterol peroxidation, the level of 3,5,7-cholestatriene in erythrocyte membranes was measured using gas chromatography-mass spectrometry, as described previously [11,15].…”

Section: Assaysmentioning

confidence: 99%

“…Different from other established serum oxidative markers, such as malondialdehyde-modified low density lipoprotein (MDA-LDL), thiobarbituric acid-reactive substances (TBARS), and 8-iso-prostaglandin F2a (8-epiPGF 2 a), 3,5,7-cholestatriene is estimated by direct measurement of the oxidative product in the cell membrane. Our previous data demonstrated that this marker correlated well with carotid artery intima-media thickness in type 2 diabetics [11]. Using this value as a marker of oxidative stress, in this study we investigated the effects of fluvastatin on oxidative stress in patients with type 2 diabetes and hyperlipidemia, and compared these effects with those of other statins.…”

mentioning

confidence: 92%

“…To elucidate whether a drug has anti-oxidative effect in clinical setting should provide important information for clinicians to help them select appropriate drugs for their diabetic patients. Recently, we established a method to measure 3,5,7-cholestatriene in erythrocyte membrane, a cholesterol oxidation product in human [11]. Different from other established serum oxidative markers, such as malondialdehyde-modified low density lipoprotein (MDA-LDL), thiobarbituric acid-reactive substances (TBARS), and 8-iso-prostaglandin F2a (8-epiPGF 2 a), 3,5,7-cholestatriene is estimated by direct measurement of the oxidative product in the cell membrane.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Anti-oxidative Effect of Fluvastatin in Hyperlipidemic Type 2 Diabetic Patients

et al. 2005

Self Cite

View full text Add to dashboard Cite

Abstract. An open-label prospective cross-over trial was performed to evaluate the antioxidative effect of fluvastatin in Japanese type 2 diabetics with hyperlipidemia. The study subjects were 10 patients who were on pravastatin (10 mg/day) or simvastatin (5 mg/day). After at least 12 weeks of continuous pravastatin or simvastatin therapy, the drugs were washed out for 12 weeks and replaced with fluvastatin (30 mg/day), then the treatment was continued for another 12 weeks. Total cholesterol and LDL cholesterol were efficiently and comparably reduced by all three statin agents. There were no differences in serum parameters of oxidative stress such as malondialdehyde-modified low-density lipoprotein, thiobarbituric acid-reactive substances, and 8-iso-prostaglandin F2a between pravastatin/simvastatin and fluvastatin. However, fluvastatin, but not pravastatin/simvastatin, significantly reduced 3,5,7-cholestatriene in erythrocyte membrane, representing the extent of membrane cholesterol peroxidation. Our data demonstrated that fluvastatin has a unique anti-oxidative effect in patients with type 2 diabetes and hyperlipidemia, compared with other statins.

show abstract

Section: Assaysmentioning

confidence: 99%

mentioning

confidence: 92%

mentioning

confidence: 99%

See 1 more Smart Citation

Anti-oxidative Effect of Fluvastatin in Hyperlipidemic Type 2 Diabetic Patients

et al. 2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…To measure MDA-LDL, an ELISA method was used that was based on the principle previously reported by Kotani et al [14]. To estimate the extent of cholesterol peroxidation, the level of 3,5,7-cholestatriene (3,5,7-Tri) in erythrocyte membranes was measured using gas chromatography-mass spectrometry, as de-scribed previously [15].…”

Section: Assaysmentioning

confidence: 99%

Efficacy and Safety of Once Daily Gliclazide (20 mg/day) Compared with Nateglinide

et al. 2004

Self Cite

View full text Add to dashboard Cite

Abstract. An open-label prospective cross-over trial was performed to compare the efficacy and safety of once daily lowdose gliclazide (20 mg/day) with that of nateglinide at the usual dosage (270 mg/day, 90 mg t.i.d.) in Japanese type 2 diabetics with relatively good glycemic control (HbA 1 c<7.0%). Eight patients received 20 mg/day of gliclazide and 16 received 270 mg/day of nateglinide. After at least 12 weeks of gliclazide or nateglinide therapy, the drugs were switched and treatment was continued for another 12 weeks. The final HbA 1 c value was modestly, but significantly, lower after gliclazide treatment than after nateglinide treatment (6.2% vs. 6.4%). However, symptoms related to hypoglycemia were significantly more common with gliclazide treatment than nateglinide treatment (7 vs. 0 cases), although there were no severe hypoglycemic events. While gliclazide acts as a free radical scavenger, there was no effect on parameters of oxidative stress such as malondialdehyde-modified low density lipoprotein and thiobarbituric acid-reactive substances at the low dosage tested. In conclusion, both drugs are reasonable options for early type 2 diabetes. Compared with the regular dose of nateglinide, 20 mg/day of gliclazide achieved modestly better glycemic control with an increased frequency of hypoglycemia in diabetic patients with relatively good glycemic control.

show abstract

“…The procedure was carried out as follows: 1 mL of washed erythrocytes solution was hypotonically lysed in 30 volumes of cold haemolysis buffer (1 mM TrisHCl, 1 mM EDTA, 10 mM NaCl, pH 7.2), mixed by vortex and allowed to stand for 15 min. Membranes were separated from the haemolysate (supernatant from haemolysed RBC) by centrifugation at 15000 rpm for 15 min at 4ºC; this step was repeated three times until a white / pale pink pellet containing haemoglobin free erythrocytes (ghosts) was obtained [23].…”

Section: Isolation Of Erythrocyte Membranesmentioning

confidence: 99%